Effects of Low-Level Laser Therapy on Oxidative Stress Levels and Quality of Life in Patients With Hashimoto Thyroiditis

Status: Completed
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Hashimoto's thyroiditis (HT) is the most commonly observed inflammatory and autoimmune disease of the thyroid gland. Recent evidence has suggested that low-level laser therapy (LLLT) can improve thyroid function and reduce levels of thyroid peroxidase antibodies (TPOAb) in patients with hypothyroidism caused by chronic autoimmune thyroiditis. In the literature, data examining the effects of LLLT on oxidative stress level and quality of life in patients with HT is limited. The aim of the study is to examine the effects of LT4 treatment combined with LLLT on thyroid autoimmunity, oxidative stress and quality of life in patients with Hashimoto's diagnosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Cases between the ages of 18-65 who applied to the Kosuyolu Istanbul Medipol Hospital Endocrinology and Metabolic Diseases Clinic between 2020-2021 and diagnosed as Hashimoto Thyroiditis by a specialist physician will be included in the study.

Locations
Other Locations
Turkey
Sümeyye TUNÇ
Istanbul
Time Frame
Start Date: 2021-02-09
Completion Date: 2022-06-30
Participants
Target number of participants: 46
Treatments
Active_comparator: Low Level Laser Therapy Group
Low Level Laser Therapy (LLLT): Low-level laser therapy will be applied to the cases in addition to LT4 hormone replacement therapy.~LLLT group will be treated using a continuous wave GaAIAs type diode laser (Intelect® Mobile Laser, Model No: 2779, Production Year: 2016; Chattanooga Group) device in the treatment area of 0.07 cm2. Continuous mode at 850 nm wavelength, 100 mW output power,1.43 W/cm2 power density and 28.57 J / cm2 energy density will be used.
Sham_comparator: Sham Group
Probes were placed in the sham laser group in a similar way as in the treatment group.
Authors
Sumeyye TUNC
Related Therapeutic Areas
Sponsors
Leads: Istanbul Medipol University Hospital

This content was sourced from clinicaltrials.gov